Measles DNA vaccine - Johns Hopkins/Vical

Drug Profile

Measles DNA vaccine - Johns Hopkins/Vical

Alternative Names: Bivalent DNA vaccine encoding measles haemagglutinin and fusion glycoproteins - Vical; Measles plasmid DNA vaccine - Vical; Vaxfectin-formulated DNA vaccine for measles - Johns Hopkins/Vical

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University; Vical
  • Class DNA vaccines; Measles vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Measles

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Measles in USA (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Measles in USA (Intradermal, Injection)
  • 21 Aug 2008 Pharmacodynamics & adverse events data from a preclinical trial in juvenile and infant rhesus macaques in Measles released by Vical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top